Optimizing the Latest Advances for Managing Early Alzheimer’s Disease
November 14, 2022
November 14, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Medical Education Resources and Enquiring Minds, LLC.
This activity is supported by an independent education grants from Lilly.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of physicians and other healthcare professionals involved in the care of Alzheimer’s disease.
Make real-world decisions, answer challenging questions and assess expert guidance as you optimize diagnostic and therapeutic strategies for those facing issues potentially related to cognitive decline and early Alzheimer’ disease.
Topics addressed include:
- Key clinical characteristics and risk factors for Alzheimer’s disease (AD)
- Clinical factors and patient-centered considerations that guide decision-making
- Diagnostic and therapeutic best practices and guidance
- Benefit-risk profiles of available and late-stage investigational agents for early AD
Upon completion of this activity, participants should be better able to:
- Describe key clinical characteristics and risk factors associated with Alzheimer’s disease (AD), and employ evidence-based tactics when diagnosing patients presenting with its symptoms
- Compare clinical trial data, safety-efficacy profiles and target patient populations for approved and investigational agents for managing early AD
- Individualize treatment decisions for patients with early AD, taking into consideration personal and clinical factors that may influence therapeutic response
Marwan Sabbagh, MD, FAAN, CCRI
Professor of Neurology, Alzheimer's and Memory Disorders Division, Barrow Neurological Institute
Research Professor, University of Arizona College of Medicine, Tucson, AZ
Clinical Professor of Neurology, Creighton University
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Enquiring Minds, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medical Education Resources designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Disclosures of Conflicts of Interest
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported conflicts of interest are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
- Marwan Sabbagh, MD, FAAN, CCRI
- Ownership interest (Stock or stock options): Athira, Cognoptix, Cortexyme, NeuroReserve, NeuroTau, Optimal Cognitive Health Company, Seq BioMarque, TransDermix, uMethod Health, Versanum
- Consultant: Alzheon, Biogen, Eisai, KeifeRx, Lilly, NeuroTherapia, Novo Nordisk, Roche-Genentech, Signant Health, Synaptogenix, T3D
- Royalties: HarperCollins, Humanix
The planners at Medical Education Resources and Enquiring Minds, LLC have no financial relationships to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this enduring activity. During the period November 11, 2022 through November 11, 2023, participants must:
- Read the learning objectives and faculty disclosures.
- Participate in the online activity.
- Complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form. Certificates will be emailed to the participant.
Course Viewing Requirements
Windows: Microsoft Edge (latest version), Google Chrome (latest version), Firefox (latest version)
Mac: Safari (latest version), Google Chrome (latest version), Firefox (latest version)
Mobile: Safari in Apple iOS/iPadOS (latest version), Google Chrome (latest version) in
Apple iOS/iPadOS (latest version), Google Chrome (latest version) in Android OS 6 or later
Required Browser Settings
Font Downloads: Must be enabled
No Compatibility View when using Internet Explorer
Screen readers: NVDA (latest version), JAWS (latest version)
Mac, Apple iOS, Apple iPadOS: VoiceOver
Android OS TalkBack (latest version)
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Enquiring Minds, LLC, Seagen and/or Merck. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
For CME questions please contact: 800-421-3756